Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study
Michelle M. Mielke(Mayo Clinic), Inga Liepelt‐Scarfone(German Center for Neurodegenerative Diseases), Walter Maetzler(Centre Hospitalier Universitaire de Lille), Rodolfo Savica(Mayo Clinic), Thomas Gasser(Hertie Institute for Clinical Brain Research), Ann‐Kathrin Hauser(German Center for Neurodegenerative Diseases), Christian Deuschle(German Center for Neurodegenerative Diseases), Susanne Gräber‐Sultan(German Center for Neurodegenerative Diseases), Veera Venkata Ratnam Bandaru(Johns Hopkins University), Daniela Berg(Christian-Albrechts-Universität zu Kiel), Erwin Schleicher(University of Tübingen), Norman J. Haughey(Tulane University)
Cited by 238
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k